Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674276 | 0.87 | KMT2A (0.59) | KMT2AGAANPSR1RXFP1KDM4E | |
| SCHEMBL7163662 | 0.85 | RAB9A (0.74) | KMT2AGAANPSR1RXFP1KDM4E | |
| SCHEMBL4927332 | 0.84 | HPGD (0.65) | KMT2AGAANPSR1RXFP1KDM4E | |
| SCHEMBL25848982 | 0.84 | KMT2A (0.56) | KMT2AGAANPSR1RXFP1KDM4E | |
| SCHEMBL7156108 | 0.81 | KMT2A (0.70) | KMT2AGAANPSR1RXFP1KDM4E | |
| SCHEMBL2203603 | 0.79 | HDAC1 (0.77) | KMT2AKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL6361569 | 0.77 | NPC1 (0.74) | KMT2AKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL8244269 | 0.75 | KMT2A (0.60) | KMT2AGAANPSR1RXFP1KDM4E | |
| SCHEMBL4919795 | 0.75 | L3MBTL1 (0.60) | KMT2AKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL6679842 | 0.75 | MGLL (0.54) | KMT2AGAANPSR1RXFP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2018-08-09 | — | — | US | disclosed |
| EP-3351541-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9938255-B2 | Metalloenzyme inhibitor compounds | VPS-3, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2788343-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS (NC) INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2016-07-28 | — | — | US | disclosed |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | NQP 1598, LTD. (KY) | 2016-07-28 | — | — | US | disclosed |
| US-9309273-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309273-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013090210-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20030232841-A1 | Heterocyclic carboxamides | PFIZER INC | 2003-12-18 | — | — | US | disclosed |
| US-6602874-B2 | 5-(2-(4-methylpiperazin-1-yl)-phenyl)- furan-2-carboxylic acid 4-chlorobenzylamide, for example; treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated | PFIZER INC. | 2003-08-05 | — | — | US | disclosed |
| US-6537995-B2 | Selective serotonin receptor agonists and antagonists used to treat migraines, depression, anxiety and schizophrenia; sertraline | PFIZER INC. | 2003-03-25 | — | — | US | disclosed |
| EP-0957099-B1 | Heterocyclic carboxamides | PFIZER PROD INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020002168-A1 | Heterocyclic carboxamides | HOWARD HARRY R (US) | 2002-01-03 | — | — | US | disclosed |
| US-20010041705-A1 | Heterocyclic carboxamides | HOWARD HARRY R (US) | 2001-11-15 | — | — | US | disclosed |
| US-6277852-B1 | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC | 2001-08-21 | — | — | US | disclosed |
| EP-0957099-A2 | Heterocyclic carboxamides | Pfizer Products Inc. (US) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002168-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | KMT2A 857/4885GAA 4243/4885NPSR1 80/4885 |
| US-20030232841-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | KMT2A 857/4885GAA 4243/4885NPSR1 80/4885 |
| US-20180222884-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KMT2A 1886/4885GAA 6/4885NPSR1 2998/4885 |
| US-20010041705-A1 | Heterocyclic carboxamides | HTR1A, HTR1D, NPY1R | KMT2A 857/4885GAA 4243/4885NPSR1 80/4885 |
| US-20140349973-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KMT2A 1886/4885GAA 6/4885NPSR1 2998/4885 |
| US-20160214959-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KMT2A 1886/4885GAA 6/4885NPSR1 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.